Abstract
Background: Colorectal cancer (CRC) is the 4th leading cause of cancer-related deaths and is in dire need of new therapeutics. Deregulation of MYC function, a proto-oncogene involved in tumorigenesis, is a feature common to most malignancies including CRC. However, no MYC inhibitor has obtained clinical approval yet. In this study, we pre-clinically validated in CRC the efficacy of Omomyc mini-protein, a MYC inhibitor developed by Dr. Soucek (Principal Investigator), which is currently in Phase I/IIa clinical trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
